In last week's C&EN, this news (article by Aayushi Pratap):
SK Pharmteco, a contract development and manufacturing organization, plans to invest $260 million in a peptide and small-molecule drug production plant in Sejong, South Korea. The 12,600 m2 facility will be the company’s fifth plant in that country. SK Pharmteco says the plant will be operational in late 2026 and add 300 employees to its workforce. The high global demand for peptides is fueled in part by the popularity of glucagon-like peptide-1 drugs, such as those developed by Novo Nordisk and Eli Lilly and Company.
It's kind of wild to me how many new peptide facilities are being set up - terribly curious to know if they will all be running in a year or five.
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20